[HTML][HTML] Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML
M Hong, H Zhu, Q Sun, Y Zhu, Y Miao, H Yang… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
We evaluated the risk status and survival outcomes of 125 elderly acute myeloid leukemia
(AML) patients treated with decitabine in combination with low-dose cytarabine, aclarubicin …
(AML) patients treated with decitabine in combination with low-dose cytarabine, aclarubicin …
Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged …
J Huang, M Hong, Y Zhu, H Zhao, X Zhang… - Leukemia & …, 2018 - Taylor & Francis
We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid
leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine …
leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine …
Efficient tumor-targeting delivery of siRNA via folate-receptor mediated biomimetic albumin nanoparticles enhanced by all-trans retinoic acid
D Wang, H Li, W Chen, H Yang, Y Liu, B You… - Materials Science and …, 2021 - Elsevier
Acute myeloid leukemia (AML) is the most universal type and fatal disease of hematological
malignancy, with poor outcomes despite chemotherapy and bone marrow transplantations …
malignancy, with poor outcomes despite chemotherapy and bone marrow transplantations …
Selection of three miRNA signatures with prognostic value in non-M3 acute myeloid leukemia
Y Xue, Y Ge, M Kang, C Wu, Y Wang, L Rong, Y Fang - BMC cancer, 2019 - Springer
Background MiRNAs that are potential biomarkers for predicting prognosis for acute myeloid
leukemia (AML) have been identified. However, comprehensive analyses investigating the …
leukemia (AML) have been identified. However, comprehensive analyses investigating the …
How to select older patients with acute myeloid leukemia fit for intensive treatment?
Z Sustkova, L Semerad… - Hematological …, 2021 - Wiley Online Library
Outcomes of the treatment of older patients with acute myeloid leukemia (AML) are
unsatisfactory due to a higher incidence of negative patient‐and disease‐related risk factors …
unsatisfactory due to a higher incidence of negative patient‐and disease‐related risk factors …
Aging of Natural Killer Cells in Acute Myeloid Leukemia
B Sanchez-Correa, R Solana, R Tarazona - Geriatric Oncology, 2020 - Springer
Aging is associated with changes in the immune system involving both adaptive and innate
immunity. Immunosenescence refers to the deterioration of the immune system function …
immunity. Immunosenescence refers to the deterioration of the immune system function …
[HTML][HTML] The prognostic factors and efficacy of induction chemotherapy in elderly patients with acute myeloid leukemia
J Mao, W Gao, L Xue, L Zhao, L Miao, T Jia… - American Journal of …, 2020 - ncbi.nlm.nih.gov
Background and objective: Acute myeloid leukemia (AML) is the most common form of
hematological malignancy in adults. We aimed to investigate the efficacy of different …
hematological malignancy in adults. We aimed to investigate the efficacy of different …
Combination therapies of hypomethylating agents for elderly patients with acute myeloid leukemia
J Huang, Y Lian, S Qian - Acta Haematologica Polonica, 2018 - journals.viamedica.pl
Older patients with acute myeloid leukemia (AML) are encumbered with poor long-term
outcomes due to patient and disease characteristics. Hypomethylating agents (HMAs) …
outcomes due to patient and disease characteristics. Hypomethylating agents (HMAs) …